A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review

被引：20

作者：

Diekstra, Meta H. M. ^{[1
]}

Swen, Jesse J. ^{[1
]}

Gelderblom, Hans ^{[2
]}

Guchelaar, Henk-Jan ^{[1
]}

机构：

[1] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands

[2] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands

来源：

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2016年 / 16卷 / 05期

关键词：

pharmacogenetics; pharmacogenomics; tyrosine kinase inhibitor; metastatic renal cell cancer; single nucleotide polymorphism; biomarker; toxicity; efficacy; SINGLE-NUCLEOTIDE POLYMORPHISMS; SUNITINIB-INDUCED TOXICITY; VEGF-TARGETED THERAPY; 1ST-LINE SUNITINIB; CLINICAL UTILITY; TREATED PATIENTS; CARCINOMA; PAZOPANIB; SORAFENIB; EXPRESSION;

D O I：

10.1586/14737159.2016.1148601

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Objective: The individual response to targeted tyrosine kinase inhibitors (TKIs) in the treatment of metastatic renal cell cancer (mRCC) is highly variable. Outlined in this article are findings on potential biomarkers for TKI treatment outcome in mRCC and an evaluation of the status of clinical implementation.Methods: Articles were selected by two independent reviewers using a systematic search in five medical databases on renal cell carcinoma, TKIs, and pharmacogenetics.Results: Many researchers have focused on predictive biomarkers for treatment outcome of targeted therapies in mRCC patients. Attempts to explain differences in efficacy and toxicity of TKIs by use of genetic variants in genes related to the pharmacokinetics and pharmacodynamics of the drug have been successful.Conclusion: Most findings on potential biomarkers have not been validated and therefore biomarker testing to guide choice of therapy and dose in mRCC is not yet feasible.

引用

页码：605 / 618

页数：14

共 80 条

[1]

[Anonymous], NEW ENGL J MED

[2] Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma [J].

Aziz, Saadia A. ;

Sznol, Joshua A. ;

Albiges, Laurence ;

Zito, Christopher ;

Jilaveanu, Lucia B. ;

Camp, Robert L. ;

Escudier, Bernard ;

Kluger, Harriet M. .

CANCER CELL INTERNATIONAL, 2014, 14

[3] A Possible Role for MicroRNA-141 Down-Regulation in Sunitinib Resistant Metastatic Clear Cell Renal Cell Carcinoma Through Induction of Epithelial-to-Mesenchymal Transition and Hypoxia Resistance [J].

Berkers, Joost ;

Govaere, Olivier ;

Wolter, Pascal ;

Beuselinck, Benoit ;

Schoeffski, Patrick ;

van Kempen, Leon C. ;

Albersen, Maarten ;

Van den Oord, Joost ;

Roskams, Tania ;

Swinnen, Johan ;

Joniau, Steven ;

Van Poppel, Hendrik ;

Lerut, Evelyne .

JOURNAL OF UROLOGY, 2013, 189 (05) :1930-1938

[4] Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib [J].

Beuselinck, B. ;

Karadimou, A. ;

Lambrechts, D. ;

Claes, B. ;

Wolter, P. ;

Couchy, G. ;

Berkers, J. ;

Paridaens, R. ;

Schoffski, P. ;

Mejean, A. ;

Verkarre, V. ;

Lerut, E. ;

de la Taille, A. ;

Tourani, J-M ;

Bigot, P. ;

Linassier, C. ;

Negrier, S. ;

Berger, J. ;

Patard, J-J ;

Zucman-Rossi, J. ;

Oudard, S. .

BRITISH JOURNAL OF CANCER, 2013, 108 (04) :887-900

[5] Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting [J].

Beuselinck, Benoit ;

Job, Sylvie ;

Becht, Etienne ;

Karadimou, Alexandra ;

Verkarre, Virginie ;

Couchy, Gabrielle ;

Giraldo, Nicolas ;

Rioux-Leclercq, Nathalie ;

Molinie, Vincent ;

Sibony, Mathilde ;

Elaidi, Reza ;

Teghom, Corinne ;

Patard, Jean-Jacques ;

Mejean, Arnaud ;

Fridman, Wolf Herman ;

Sautes-Fridman, Catherine ;

de Reynies, Aurelien ;

Oudard, Stephane ;

Zucman-Rossi, Jessica .

CLINICAL CANCER RESEARCH, 2015, 21 (06) :1329-1339

[6] Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib [J].

Beuselinck, Benoit ;

Lambrechts, Diether ;

Van Brussel, Thomas ;

Wolter, Pascal ;

Cardinaels, Nina ;

Joniau, Steven ;

Lerut, Evelyne ;

Karadimou, Alexandra ;

Couchy, Gabrielle ;

Sebe, Philippe ;

Ravaud, Alain ;

Zerbib, Marc ;

Caty, Armelle ;

Paridaens, Robert ;

Schoffski, Patrick ;

Verkarre, Virginie ;

Berger, Julien ;

Patard, Jean-Jacques ;

Zucman-Rossi, Jessica ;

Oudard, Stephane .

ACTA ONCOLOGICA, 2014, 53 (10) :1413-1422

[7] VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis [J].

Beuselinck, Benoit ;

Karadimou, Alexandra ;

Lambrechts, Diether ;

Claes, Bart ;

Wolter, Pascal ;

Couchy, Gabrielle ;

Berkers, Joost ;

van Poppel, Hendrik ;

Paridaens, Robert ;

Schoffski, Patrick ;

Mejean, Arnaud ;

Verkarre, Virginie ;

Lerut, Evelyne ;

Joly, Florence ;

Lebret, Thierry ;

Gravis, Gwenaelle ;

Deplanque, Gael ;

Descazeaud, Aurelien ;

Leclercq, Nathalie Rioux ;

Molinie, Vincent ;

Patard, Jean-Jacques ;

Teghom, Corine ;

Elaidi, Reza ;

Zucman-Rossi, Jessica ;

Oudard, Stephane .

ACTA ONCOLOGICA, 2014, 53 (01) :103-112

[8] Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status [J].

Bhargava, Pankaj ;

Robinson, Murray O. .

CURRENT ONCOLOGY REPORTS, 2011, 13 (02) :103-111

[9] Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process [J].

Caudle, Kelly E. ;

Klein, Teri E. ;

Hoffman, James M. ;

Mueller, Daniel J. ;

Whirl-Carrillo, Michelle ;

Gong, Li ;

McDonagh, Ellen M. ;

Sangkuhl, Katrin ;

Thorn, Caroline F. ;

Schwab, Matthias ;

Agundez, Jose A. G. ;

Freimuth, Robert R. ;

Huser, Vojtech ;

Lee, Ming Ta Michael ;

Iwuchukwu, Otito F. ;

Crews, Kristine R. ;

Scott, Stuart A. ;

Wadelius, Mia ;

Swen, Jesse J. ;

Tyndale, Rachel F. ;

Stein, C. Michael ;

Roden, Dan ;

Relling, Mary V. ;

Williams, Marc S. ;

Johnson, Samuel G. .

CURRENT DRUG METABOLISM, 2014, 15 (02) :209-217

[10] A Multigene Assay Identifying Distinct Prognostic Subtypes of Clear Cell Renal Cell Carcinoma with Differential Response to Tyrosine Kinase Inhibition [J].

Choudhury, Yukti ;

Wei, Xiaona ;

Chu, Ying-Hsia ;

Ng, Lay Guat ;

Tan, Hui Shan ;

Koh, Valerie ;

Thike, Aye Aye ;

Poon, Eileen ;

Ng, Quan Sing ;

Toh, Chee Keong ;

Kanesvaran, Ravindran ;

Tan, Puay Hoon ;

Tan, Min-Han .

EUROPEAN UROLOGY, 2015, 67 (01) :17-20

← 1 2 3 4 5 6 7 8 →